全文获取类型
收费全文 | 672篇 |
免费 | 34篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 210篇 |
妇产科学 | 16篇 |
基础医学 | 101篇 |
口腔科学 | 11篇 |
临床医学 | 23篇 |
内科学 | 103篇 |
皮肤病学 | 10篇 |
神经病学 | 23篇 |
特种医学 | 5篇 |
外科学 | 83篇 |
综合类 | 17篇 |
预防医学 | 15篇 |
眼科学 | 37篇 |
药学 | 23篇 |
中国医学 | 1篇 |
肿瘤学 | 26篇 |
出版年
2024年 | 2篇 |
2023年 | 9篇 |
2022年 | 12篇 |
2021年 | 26篇 |
2020年 | 21篇 |
2019年 | 33篇 |
2018年 | 27篇 |
2017年 | 29篇 |
2016年 | 20篇 |
2015年 | 19篇 |
2014年 | 28篇 |
2013年 | 43篇 |
2012年 | 51篇 |
2011年 | 52篇 |
2010年 | 35篇 |
2009年 | 28篇 |
2008年 | 48篇 |
2007年 | 42篇 |
2006年 | 35篇 |
2005年 | 24篇 |
2004年 | 23篇 |
2003年 | 25篇 |
2002年 | 19篇 |
2001年 | 10篇 |
2000年 | 12篇 |
1999年 | 3篇 |
1998年 | 5篇 |
1996年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有706条查询结果,搜索用时 15 毫秒
1.
Interactions Between Cytomegalovirus, Human Herpesvirus-6, and the Recurrence of Hepatitis C After Liver Transplantation 总被引:1,自引:0,他引:1
Atul Humar Deepali Kumar Janet Raboud Angela M. Caliendo George Moussa Gary Levy Tony Mazzulli 《American journal of transplantation》2002,2(5):461-466
Recurrence of hepatitis C (HCV) following liver transplantation is common. Herpesvirus reactivation following transplant may have an immunomodulatory effect resulting in increased HCV replication. We studied whether cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) may be associated with HCV recurrence and viral load after transplant. We prospectively followed 66 HCV liver-transplant recipients with serial viral load testing for CMV and HHV-6. Infection and viral load were correlated with the development of biopsy-proven HCV recurrence and HCV viral loads. Histologic recurrence of HCV occurred in 41/66 (62.1%) patients. In the primary analysis, CMV infection and disease, and HHV-6 infection were not associated with HCV recurrence. Peak CMV and HHV-6 viral loads were not significantly different in patients with and without recurrence. No correlation was observed between HCV viral loads at 1 and 3 months post-transplant and peak HHV-6 or CMV viral loads. In a subgroup analysis, HHV-6 infection was associated with the development of more severe recurrence (hepatitis and/or fibrosis score > or = 2) (p = 0.01). Also, fibrosis scores at last follow up were higher in patients with CMV disease (1.67 vs. 0.56; p = 0.016) and in patients with HHV-6 infection (1.18 vs. 0.55; p = 0.031). In conclusion, HHV-6 and CMV infection and viral load were not associated with increased overall rates of HCV recurrence or HCV viral load after liver transplantation but may be associated with more severe forms of recurrence. 相似文献
2.
Deepali Kumar Dean Erdman Shaf Keshavjee Teresa Peret Raymond Tellier Denis Hadjiliadis Grant Johnson Melissa Ayers Deborah Siegal Atul Humar 《American journal of transplantation》2005,5(8):2031-2036
Community-acquired viral respiratory tract infections (RTI) in lung transplant recipients may have a high rate of progression to pneumonia and can be a trigger for immunologically mediated detrimental effects on lung function. A cohort of 100 patients was enrolled from 2001 to 2003 in which 50 patients had clinically diagnosed viral RTI and 50 were asymptomatic. All patients had nasopharyngeal and throat swabs taken for respiratory virus antigen detection, culture and RT-PCR. All patients had pulmonary function tests at regular intervals for 12 months. Rates of rejection, decline in forced expiratory volume (L) in 1 s (FEV-1) and bacterial and fungal superinfection were compared at the 3-month primary endpoint. In the 50 patients with RTI, a microbial etiology was identified in 33 of 50 (66%) and included rhinovirus (9), coronavirus (8), RSV (6), influenza A (5), parainfluenza (4) and human metapneumovirus (1). During the 3-month primary endpoint, 8 of 50 (16%) RTI patients had acute rejection versus 0 of 50 non-RTI patients (p=0.006). The number of patients experiencing a 20% or more decline in FEV-1 by 3 months was 9 of 50 (18%) RTI versus 0 of 50 non-RTI (0%) (p=0.003). In six of these nine patients, the decline in FEV-1 was sustained over a 1-year period consistent with bronchiolitis obliterans syndrome (BOS). Community-acquired respiratory viruses may be associated with the development of acute rejection and BOS. 相似文献
3.
Cedric Hirzel Arnaud G. L'Huillier Victor H. Ferreira Tina Marinelli Terrance Ku Matthew Ierullo Congrong Miao D. Scott Schmid Stephen Juvet Atul Humar Deepali Kumar 《American journal of transplantation》2021,21(6):2246-2253
Lung transplant recipients are at high risk for herpes zoster and preventive measures are a significant unmet need. We investigated the safety and immunogenicity of two doses of a recombinant zoster vaccine (RZV) in lung transplant recipients (≥50 years). We enrolled 50 patients of which 49 received at least one vaccine dose. Anti-glycoprotein E (gE) antibody levels (n = 43) increased significantly compared to baseline (median optical density [OD] 1.96; interquartile range [IQR]: 1.17–2.89) after the first (median OD 3.41, IQR 2.54–3.81, p < .0001) and second vaccine dose (median OD 3.63, IQR 3.39–3.86, p < .0001). gE-specific polyfunctional CD4+ T cell frequencies (n = 38) also increased from baseline (median 85 per 106 CD4+ T cells; IQR: 46–180) to the first (median 128 per 106 CD4+ T cells; IQR: 82–353; p = .023) and after the second dose (median 361 per 106 CD4+ T cells; IQR: 146–848; p < .0001). Tenderness (83.0%; 95%CI: 69.2–92.4%) and redness (31.9%; 95%CI: 19.1–47.1%) at injection site were common. One rejection episode within 3 weeks of vaccination was observed. This is the first study demonstrating that RZV was safe and elicited significant humoral and cell-mediated immunity in lung transplant recipients. RZV is a new option for the prevention of shingles in this population. 相似文献
4.
5.
Gupta Sumita Mukherjee Aparna Lodha Rakesh Kabra Madhulika Deepak Kishore K. Khadgawat Rajesh Talwar Anjana Kabra Sushil Kumar 《Indian journal of pediatrics》2019,86(11):987-994
Indian Journal of Pediatrics - To evaluate effect of one year exercise intervention program on bone mineral accrual in children and adolescent with cystic fibrosis (CF). Fifty-two CF children (mean... 相似文献
6.
Kumar D Rotstein C Miyata G Arlen D Humar A 《The Journal of infectious diseases》2003,187(10):1639-1645
Renal transplant recipients are at increased risk for developing invasive pneumococcal disease but may have a poor response to pneumococcal polysaccharide vaccine (PPV23). For them, pneumococcal conjugate vaccine (PCV7) may be more immunogenic. Patients were given a single dose of PPV23 or PCV7 in our randomized, controlled, double-blind trial. Immunogenicity was assessed 8 weeks after vaccination by serotype-specific enzyme-linked immunosorbent assay (ELISA) and opsonophagocytic assay (OPA). Baseline demographics, renal function, time since transplantation, and immunosuppression were comparable. In the PCV7 group, the vaccine response rate was improved for serotypes 23F (P=.046) and 6B (P=.067), and mean fold increases in antibody titer were higher for serotypes 23F (P=.046) and 9V (P=.09). The response rate and mean fold increase in OPA titers were not significantly different between groups. There was a trend toward enhanced immunogenicity for PCV7 by ELISA. However, functional antibody responses were not different. 相似文献
7.
8.
Cytomegalovirus (CMV) can be classified into 4 glycoprotein B (gB) genotypes, on the basis of sequence variation in the UL55 gene. We assessed the effect that CMV gB genotype has on virologic and clinical response to therapy, in 50 solid-organ-transplant recipients with CMV disease. CMV loads were determined at regular intervals after the start of therapy. Genotype results were correlated with CMV-load kinetics in response to therapy with ganciclovir. At the onset of treatment, the distribution of CMV gB genotypes was as follows: gB1, 19/50 (38%); gB2, 9/50 (18%); gB3, 12/50 (24%); gB4, 2/50 (4%); and mixed-genotype infection, 8/50 (16%). Between viral genotype groups, time to clearance of CMV, failure to clear CMV, and calculated CMV-load half-life after the start of therapy were not significantly different. The CMV gB genotype did not affect the rate of disease recurrence or occurrence of tissue-invasive disease. It appears that the gB genotype, which causes CMV disease, does not significantly influence CMV-load kinetics or clinical response to therapy. 相似文献
9.
10.
Chih‐Yi Liu Andrey Bychkov Shipra Agarwal Yun Zhu Jen‐Fan Hang Chiung‐Ru Lai Hee Young Na Weiwei Li Zhiyan Liu Deepali Jain Ayana Suzuki Mitsuyoshi Hirokawa Noel Chia Min En Nga Tikamporn Jitpasutham Somboon Keelawat So Yeon Park Shinya Satoh Chien‐Chin Chen Dilini Gunawardena Priyanthi Kumarasinghe Chan Kwon Jung Kennichi Kakudo 《Diagnostic cytopathology》2021,49(1):60-69